Germany · Delayed Price · Currency is EUR PEPTONIC medical AB Statistics
Total Valuation
FRA:28L has a market cap or net worth of EUR 8.20 million. The enterprise value is 7.89 million.
| Market Cap | 8.20M |
| Enterprise Value | 7.89M |
Important Dates
The next estimated earnings date is Sunday, February 22, 2026.
| Earnings Date | Feb 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 9.34B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +30.83% |
| Shares Change (QoQ) | +1.88% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.78 |
| PB Ratio | 2.34 |
| P/TBV Ratio | 3.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.78 |
| EV / Sales | 5.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.66 |
Financial Position
The company has a current ratio of 0.49, with a Debt / Equity ratio of 0.40.
| Current Ratio | 0.49 |
| Quick Ratio | 0.13 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.65 |
| Interest Coverage | -25.63 |
Financial Efficiency
Return on equity (ROE) is -86.89% and return on invested capital (ROIC) is -43.25%.
| Return on Equity (ROE) | -86.89% |
| Return on Assets (ROA) | -37.48% |
| Return on Invested Capital (ROIC) | -43.25% |
| Return on Capital Employed (ROCE) | -121.55% |
| Revenue Per Employee | 473,178 |
| Profits Per Employee | -1.48M |
| Employee Count | 27 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 0.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 39.38 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:28L had revenue of EUR 1.42 million and -4.43 million in losses. Loss per share was -0.00.
| Revenue | 1.42M |
| Gross Profit | 936,347 |
| Operating Income | -4.27M |
| Pretax Income | -4.43M |
| Net Income | -4.43M |
| EBITDA | -4.09M |
| EBIT | -4.27M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 82,129 in cash and 1.41 million in debt, giving a net cash position of -1.33 million.
| Cash & Cash Equivalents | 82,129 |
| Total Debt | 1.41M |
| Net Cash | -1.33M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 3.51M |
| Book Value Per Share | 0.00 |
| Working Capital | -1.35M |
Cash Flow
In the last 12 months, operating cash flow was -2.16 million and capital expenditures 8,774, giving a free cash flow of -2.15 million.
| Operating Cash Flow | -2.16M |
| Capital Expenditures | 8,774 |
| Free Cash Flow | -2.15M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 65.96% |
| Operating Margin | -300.71% |
| Pretax Margin | -312.09% |
| Profit Margin | n/a |
| EBITDA Margin | -288.40% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:28L does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.83% |
| Shareholder Yield | -30.83% |
| Earnings Yield | -54.00% |
| FCF Yield | -26.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:28L has an Altman Z-Score of -10.11 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.11 |
| Piotroski F-Score | 2 |